Cohance Lifesciences shares worth ₹3,073 crore change hands in block deals; Stock falls 6%

As many as 3.39 crore shares, or 8.9% equity of Cohance Lifesciences worth ₹3,073 crore changed hands via block deals on Thursday, September 18. The stock fell over 6% in opening trading.

Earlier in the day, sources told CNBC-TV18 that Jusmiral Holdings was likely to sell 8.9% stake or 34.1 million shares in Cohance Lifesciences for $350 million via block deals. 

A day prior, sources had told CNBC-TV18 that Jusmiral Holdings was to sell up to 5.1% of its stake in Cohance Lifesciences Ltd. via block deals.

Sources said the offer size was estimated at ₹1,756 crore, with a floor price of ₹900 per share, representing a 6.9% discount to the stock’s previous close.

A lock-up period of 210 days is to be set for any further share sales, the sources added.

IIFL Capital is the book-running lead manager for the transaction, sources said.

At the end of the June quarter, Jusmiral Holdings held 33.34% stake in Cohance Lifesciences, as per data available on the stock exchanges.

Cohance Lifesciences is a Hyderabad-based contract development and manufacturing organisation (CDMO) company. It offers services to international pharma, biotech and fine chemicals companies, taking projects from early-stage research through to commercial manufacturing.

In May 2025, Cohance Lifesciences officially changed its name from Suven Pharmaceuticals.

Shares of Cohance Lifesciences ended the previous session 2.5% lower at ₹965.5 apiece. The stock has gained 7.6% in the past month but has declined 9.7% in the last six months.

Also Read: PN Gadgil shares worth ₹5,441 crore to free up as lock-in period ends